Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy

被引:289
作者
Sinicrope, Frank A. [1 ,2 ]
Mahoney, Michelle R. [1 ,2 ]
Smyrk, Thomas C. [1 ,2 ]
Thibodeau, Stephen N. [1 ,2 ]
Warren, Robert S. [3 ]
Bertagnolli, Monica M. [4 ]
Nelson, Garth D. [1 ,2 ]
Goldberg, Richard M. [5 ]
Sargent, Daniel J. [1 ,2 ]
Alberts, Steven R. [1 ,2 ]
机构
[1] Mayo Clin, Mayo Canc Ctr, Rochester, MN 55905 USA
[2] North Cent Canc Treatment Grp, Rochester, MN USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
[5] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
关键词
TUMOR MICROSATELLITE-INSTABILITY; COLORECTAL-CANCER; BRAF MUTATION; FLUOROURACIL; SURVIVAL; KRAS; OXALIPLATIN; LEUCOVORIN; TUMORIGENESIS; MORPHOLOGY;
D O I
10.1200/JCO.2013.48.9591
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose The association of deficient DNA mismatch repair (dMMR) with prognosis in patients with colon cancer treated with adjuvant fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy remains unknown. Patients and Methods Resected, stage III colon carcinomas from patients (N = 2,686) randomly assigned to FOLFOX +/- cetuximab (North Central Cancer Treatment Group N0147 trial) were analyzed for mismatch repair (MMR) protein expression and mutations in BRAF(V600E) (exon 15) and KRAS (codons 12 and 13). Association of biomarkers with disease-free survival (DFS) was determined using Cox models. A validation cohort (Cancer and Leukemia Group B 88903 trial) was used. Results dMMR was detected in 314 (12%) of 2,580 tumors, of which 49.3% and 10.6% had BRAF(V600E) or KRAS mutations, respectively. MMR status was not prognostic overall (adjusted hazard ratio [HR], 0.82; 95% CI, 0.64 to 1.07; P = .14), yet significant interactions were found between MMR and primary tumor site (P-interaction = .009) and lymph node category (N1 v N2; P-interaction = .014). Favorable DFS was observed for dMMR versus proficient MMR proximal tumors (HR, 0.71; 95% CI, 0.53 to 0.94; P = .018) but not dMMR distal tumors (HR, 1.71; 95% CI, 0.99 to 2.95; P = .056), adjusting for mutations and covariates. Any survival benefit of dMMR was lost in N2 tumors. Mutations in BRAF(V600E) (HR, 1.37; 95% CI, 1.08 to 1.70; P .009) or KRAS (HR, 1.44; 95% CI, 1.21 to 1.70; P .001) were independently associated with worse DFS. The observed MMR by tumor site interaction was validated in an independent cohort of stage III colon cancers (P-interaction = .037). Conclusion The prognostic impact of MMR depended on tumor site, and this interaction was validated in an independent cohort. Among dMMR cancers, proximal tumors had favorable outcome, whereas distal or N2 tumors had poor outcome. BRAF or KRAS mutations were independently associated with adverse outcome.
引用
收藏
页码:3664 / +
页数:10
相关论文
共 42 条
[1]
Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer A Randomized Trial [J].
Alberts, Steven R. ;
Sargent, Daniel J. ;
Nair, Suresh ;
Mahoney, Michelle R. ;
Mooney, Margaret ;
Thibodeau, Stephen N. ;
Smyrk, Thomas C. ;
Sinicrope, Frank A. ;
Chan, Emily ;
Gill, Sharlene ;
Kahlenberg, Morton S. ;
Shields, Anthony F. ;
Quesenberry, James T. ;
Webb, Thomas A. ;
Farr, Gist H., Jr. ;
Pockaj, Barbara A. ;
Grothey, Axel ;
Goldberg, Richard M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (13) :1383-1393
[2]
American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy [J].
Allegra, Carmen J. ;
Jessup, J. Milburn ;
Somerfield, Mark R. ;
Hamilton, Stanley R. ;
Hammond, Elizabeth H. ;
Hayes, Daniel F. ;
McAllister, Pamela K. ;
Morton, Roscoe F. ;
Schilsky, Richard L. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (12) :2091-2096
[3]
Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[4]
A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations A Morphology-Based Approach in Colorectal Carcinoma [J].
Angulo, Barbara ;
Garcia-Garcia, Elena ;
Martinez, Rebeca ;
Suarez-Gauthier, Ana ;
Conde, Esther ;
Hidalgo, Manuel ;
Lopez-Rios, Fernando .
JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (03) :292-299
[5]
[Anonymous], SEER CANC STAT REV
[6]
Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 [J].
Bertagnolli, Monica M. ;
Niedzwiecki, Donna ;
Compton, Carolyn C. ;
Hahn, Hejin P. ;
Hall, Margaret ;
Damas, Beatrice ;
Jewell, Scott D. ;
Mayer, Robert J. ;
Goldberg, Richard M. ;
Saltz, Leonard B. ;
Warren, Robert S. ;
Redston, Mark .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1814-1821
[7]
Mismatch repair proficiency and in vitro response to 5-fluorouracil [J].
Carethers, JM ;
Chauhan, DP ;
Fink, D ;
Nebel, S ;
Bresalier, RS ;
Howell, SB ;
Boland, CR .
GASTROENTEROLOGY, 1999, 117 (01) :123-131
[8]
COX DR, 1972, J R STAT SOC B, V34, P187
[9]
Mutations of the BRAF gene in human cancer [J].
Davies, H ;
Bignell, GR ;
Cox, C ;
Stephens, P ;
Edkins, S ;
Clegg, S ;
Teague, J ;
Woffendin, H ;
Garnett, MJ ;
Bottomley, W ;
Davis, N ;
Dicks, N ;
Ewing, R ;
Floyd, Y ;
Gray, K ;
Hall, S ;
Hawes, R ;
Hughes, J ;
Kosmidou, V ;
Menzies, A ;
Mould, C ;
Parker, A ;
Stevens, C ;
Watt, S ;
Hooper, S ;
Wilson, R ;
Jayatilake, H ;
Gusterson, BA ;
Cooper, C ;
Shipley, J ;
Hargrave, D ;
Pritchard-Jones, K ;
Maitland, N ;
Chenevix-Trench, G ;
Riggins, GJ ;
Bigner, DD ;
Palmieri, G ;
Cossu, A ;
Flanagan, A ;
Nicholson, A ;
Ho, JWC ;
Leung, SY ;
Yuen, ST ;
Weber, BL ;
Siegler, HF ;
Darrow, TL ;
Paterson, H ;
Marais, R ;
Marshall, CJ ;
Wooster, R .
NATURE, 2002, 417 (6892) :949-954
[10]
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712